ORBIMED ADVISORS LLC 13D and 13G filings for Kinnate Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-21 4:11 pm Unchanged |
2024-02-16 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 7,559,729 16.100% |
0 (Unchanged) |
Filing |
| 2023-11-17 08:27 am Unchanged |
2023-11-17 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 7,559,729 16.000% |
0 (Unchanged) |
Filing |
| 2023-11-14 4:57 pm Unchanged |
2023-11-13 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 7,559,729 16.000% |
0 (Unchanged) |
Filing |
| 2023-05-08 5:01 pm Purchase |
2023-05-04 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 7,559,729 16.200% |
1,460,932 (+23.95%) |
Filing |
| 2023-05-02 7:28 pm Purchase |
2023-04-28 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 6,098,797 13.100% |
1,405,168 (+29.94%) |
Filing |
| 2023-02-23 3:23 pm Purchase |
2023-02-17 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 4,693,629 10.600% |
1,295,700 (+38.13%) |
Filing |
| 2020-12-11 4:39 pm Purchase |
2020-12-02 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 3,397,929 7.800% |
3,397,929 (New Position) |
Filing |